06 Nov 2026, 06:42 IST
Aurobindo Pharma Limited
HDFC Securities · ADD · target INR1,950
The report says Aurobindo's EBITDA grew 28% YoY, ahead of estimates, with FY27 guidance retained, and revises TP to INR1,950 maintaining ADD.
From HSIE Results Daily 06 Nov 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.